UK On A Knife Edge As EU Referendum Nears
Executive Summary
With the UK about to go to the polls in a once-and-for-all decision on EU membership, the stakes for the life sciences sector are high. The effects of a Brexit would be far-reaching, not only for the industry but also for other key groups such as regulators, patients and researchers.
You may also be interested in...
'We Cannot Afford To Be An Island': Bayer's UK CEO Shares Anti-Brexit Opinion
In the lead up to the June 23 referendum to decide whether Britain should leave or remain in the European Union, Dr. Alexander Moscho, CEO of Bayer UK & Ireland, shares his opinion on how leaving the EU could be a setback for life sciences and impact patients significantly in regard to access to medicines.
ABPI And Top Pharma Execs Come Out Against Brexit
The Association of the British Pharmaceutical Industry has formally come out in support of the UK remaining part of the EU, saying that a vote to leave in next month's referendum would lead to delays in the availability of new drugs, have a detrimental effect on collaboration in European drug research, and discourage inward investment by international drug firms.
EU Referendum: EFPIA, Witty And Soriot Show Their Hands
Pharmaceutical industry associations have until recently remained pretty quiet over the prospect of a British exit from the EU. But following the announcement that the referendum will be held on June 23, that seems to be changing.